French Connect : A liquid biopsy platform for highly sensitive ctDNA-based MRD monitoring in lymphoid malignancies.
Design, validate or accelerate clinical development with expert infrastructures.
Offer overview
What this offer helps you achieve
Design, validate or accelerate clinical development with expert infrastructures.
Scientific and technical scope
French Connect is an innovative liquid biopsy platform for sensitive ctDNA-based MRD monitoring in lymphoid malignancies research. It enables early relapse prediction (PET-scan correlated), MRD follow-up in clinical trials, and ancillary studies. Developed by multi-disciplinary experts from 10 leading French academic centers, this platform offers ready-to-use panels for DLBCL, PMBL, and FL, along with an optimized bioinformatics pipeline. Additional panels for HL, MCL, and T-cell lymphomas are also in development to complete our offer.
Capabilities mobilised
Therapeutic areasExpert adviceClinical validationPlatforms
Application fields
Oncology
Discuss this offer
Could this capability strengthen your R&D programme?
Present your scientific, technical or clinical need and identify the most relevant route to collaboration.
Continue exploring
Related expertise for your programme
Offers selected through shared capabilities, application fields or institute expertise.
